the crisPr-cas9 system is commonly used in biomedical research; however, the precision of cas9 is suboptimal for applications that involve editing a large population of cells (for example, gene therapy). Variations on the standard cas9 system have yielded improvements in the precision of targeted dnA cleavage, but they often restrict the range of targetable sequences. it remains unclear whether these variants can limit lesions to a single site in the human genome over a large cohort of treated cells. here we show that by fusing a programmable dnA-binding domain (pdBd) to cas9 and attenuating cas9's inherent dnA-binding affinity, we were able to produce a cas9-pdBd chimera with dramatically improved precision and an increased targeting range. Because the specificity and affinity of this framework can be easily tuned, cas9-pdBds provide a flexible system that can be tailored to achieve extremely precise genome editing at nearly any genomic locus.
The CRISPR-Cas9 genome engineering system is revolutionizing biological sciences owing to its simplicity and efficacy [1] [2] [3] . The most commonly studied Cas9 nuclease (SpCas9) originates from Streptococcus pyogenes 4 . SpCas9 and its associated guide RNA license a DNA sequence for cleavage on the basis of two stages of sequence interrogation [4] [5] [6] [7] [8] (Supplementary Fig. 1 ):
(1) compatibility of the protospacer-adjacent motif (PAM) element with the specificity of the PAM-interacting domain, and (2) complementarity of the guide RNA sequence to the target site. As it is straightforward to program Cas9 to cleave a desired target site through the incorporation of a complementary single guide RNA (sgRNA) 4 , the primary constraint on Cas9 targeting is the presence of a compatible PAM element 4, 9, 10 . The PAMinteracting domain of wild-type SpCas9 preferentially recognizes an NGG element 4 , although it can inefficiently utilize other PAM sequences (for example, NAG and NGA) 9, 11 . The simplicity of the SpCas9-sgRNA system allows facile editing of genomes in a variety of organisms and cell lines [1] [2] [3] .
The precision of SpCas9 is suboptimal for most gene therapy applications involving editing of a large population of cells 12, 13 . genome at unintended sites 9, [14] [15] [16] [17] [18] [19] [20] , with some guides acting at more than 100 off-target sites 17 . Recent genome-wide analyses of SpCas9 precision indicate that the majority of genomic loci that differ from the guide RNA sequence at two nucleotides and a subset of genomic loci that differ at three nucleotides are cleaved with moderate activity [17] [18] [19] [20] . For some guides, off-target sites that differ by up to six nucleotides can be inefficiently cleaved [17] [18] [19] [20] , and bulges can be accommodated in the sgRNA:DNA heteroduplex 15 . In this light, we assessed the general frequency of potential off-target sites with three or fewer mismatches for SpCas9 guide RNAs in exons or promoter regions using CRISPRseek 21, 22 . We found that the vast majority of guides (~98% in exons and ~99% in promoters) had one or more off-target sites with three or fewer mismatches (Supplementary Fig. 1 ) and thus were likely to have some level of off-target activity. Because off-target breaks have the potential to cause both local mutagenesis and genomic rearrangements 17, 18, 23, 24 (for example, segmental deletions, inversions and translocations), the resulting collateral damage from SpCas9 treatment could have adverse consequences in therapeutic applications.
Decreased off-target cleavage rates have been associated with several modifications to the structure or delivery of the CRISPRCas9 system, such as changes to the guide sequence length and composition 25, 26 , the use of a pair of Cas9 nickases [26] [27] [28] or FokIdCas9 nucleases 10, 29 , inducible assembly of split Cas9 (refs. 30-33) , Cas9 PAM variants with enhanced specificity 34 and the delivery of Cas9:sgRNA ribonucleoprotein complexes [35] [36] [37] . However, it remains unknown whether these variations can restrict cleavage to a single site in the human genome over a large cohort of treated cells 12, 38 . In addition, some of the most promising approaches (for example, paired nickases and dimeric FokI-dCas9) restrict the targetable sequence space by requiring the proximity of two sequences compatible with Cas9 recognition.
We envisioned an improved Cas9 platform in which the precision of target recognition was augmented by the incorporation of pDBDs such as Cys 2 -His 2 zinc-finger proteins 39 (ZFPs) or transcription activator-like effectors 40 (TALEs) (Fig. 1a and Supplementary Fig. 2 ). Both of these pDBD platforms can be Bottom, activity profiles of SpCas9 (blue, on an NGG or NAG PAM), SpCas9-Zif268 (red, NAG PAM) and SpCas9-TAL268 (brown, NAG PAM) in the GFP reporter assay on a common sgRNA target site. The pDBD-site orientation was either W or C, and spacing was 5, 8, 11 or 14 bp from the PAM. (c) Activity profile of SpCas9 (blue) and SpCas9-Zif268 (red) in the GFP reporter assay on a common target site with different PAM sequences and a neighboring Zif268 site. (d) Top, SpCas9 or SpCas9-Zif268 programmed independently with four different sgRNAs targeting four different genomic sites with neighboring Zif268 binding sites (highlighted in orange). Bottom, SpCas9 cut efficiently only at the target site with an NGG PAM, but SpCas9-Zif268 cut efficiently at additional target sites with NAG, NGA and NGC PAMs. Genomic regions were PCR amplified, and lesions (indicating cleavage and mutagenic non-homologous end joining) were detected by T7EI assay. NegCT indicates untreated cells. (e) Quantification of lesion frequency from three independent biological replicates performed on different days in HEK293T cells. Error bars indicate ±s.e.m.
programmed to recognize nearly any sequence in the genome [39] [40] [41] [42] . Indeed, pDBDs have been used with great success as targeting domains for programmable nucleases through the incorporation of nonspecific FokI nuclease domains (zinc-finger nucleases 39 and TALE nucleases 40 ) or sequence-specific nuclease domains (e.g., megaTAL 43 ). One favorable characteristic of pDBDs is their inherent modularity whereby specificity and affinity can be rationally tuned by adjustments to the number and composition of incorporated modules and the linkage between modules 44, 45 . Here we demonstrate that the fusion of a pDBD to a mutant SpCas9 with attenuated DNA-binding affinity generated a chimeric nuclease with a broader sequence-targeting range and dramatically improved precision. This SpCas9-pDBD platform has favorable properties for genome engineering applications. In addition, our analysis of these SpCas9-pDBD chimeras provides new insights into the barriers involved in licensing target-site cleavage by a SpCas9:sgRNA complex. results defining the properties of the spcas9-pdBd framework To define the parameters necessary for the function of a SpCas9-pDBD chimera, we assayed the cleavage of a Cas9:sgRNA target site with a suboptimal NAG PAM using a plasmid reporter assay 46 . We examined the ability of a pDBD fused (ZFP or TALE) to SpCas9 to enhance nuclease activity when the pDBD binding sites were located at different positions and orientations relative to the Cas9 target site (Fig. 1b) . In pilot experiments, we observed the most robust activity when we used a C-terminal fusion of a ZFP or a TALE to SpCas9 when the pDBD binding sites were positioned 3′ to the PAM element (M.F.B. and S.A.W., unpublished results). Both SpCas9-ZFP and SpCas9-TALE proteins increased nuclease activity on an NAG PAM target to a level similar to the activity of wild-type SpCas9 on an NGG PAM (Fig. 1b) while being expressed at similar levels ( Supplementary Fig. 3 ). SpCas9-pDBD nuclease activity remained dependent on the length of the guide sequence ( Supplementary Fig. 4 ), confirming that the chimera retained the guide-dependent licensing stage for sequence cleavage. To define the functional PAM elements for SpCas9-pDBD, we examined activity at each of the 16 possible sequence combinations. In contrast to wild-type SpCas9, SpCas9-pDBD demonstrated high activity for NAG, NGA and NGC as well as for the standard NGG PAM (Fig. 1c and Supplementary  Fig. 5 ). Accounting for reverse complements of the functional PAM elements, the SpCas9-pDBD chimeras recognized 7 of the 16 possible dinucleotide sequence combinations. The increased targeting range for SpCas9-pDBDs was also observed at genomic target sites (Fig. 1d,e) . Because of the smaller size of SpCas9-ZFPs relative to SpCas9-TALEs, which confers advantages for certain viral-delivery systems 47 , we focused primarily on SpCas9-ZFP chimeras for the immediate development of this platform.
Attenuating the dnA-binding activity of spcas9
The fusion of a pDBD to SpCas9 should increase nuclease precision if target cleavage is dependent on DNA recognition by the pDBD. To test this, we attenuated the DNA-binding affinity of SpCas9 by independently mutating the key PAM recognition residues 7 (Arg1333 and Arg1335) to either lysine or serine ( Fig. 2a and Supplementary Fig. 6 ). In the plasmid reporter assay, all four mutations decreased the nuclease activity of SpCas9 to background levels. A ZFP fusion in the presence of a complementary binding site restored nuclease activity in all mutants except R1335S (SpCas9 MT4 ) (Fig. 2b) . We found that R1335K (SpCas9 MT3 ) lacked activity with the NAG PAM even as a SpCas9-ZFP fusion. This prompted a broader assessment of PAM specificity for the three active SpCas9-ZFP mutants, which revealed a preference for alternate PAMs that preserved the remaining arginine-guanine interaction 7 (i.e., R1333 mutants preferred NNG PAMs, whereas the R1335K mutant preferred NGN PAMs; Supplementary Fig. 6 ). The activity of each SpCas9 mutant was also characterized on compatible genomic target sites with an NGG PAM. R1333K (SpCas9 MT1 ) retained independent activity on a subset of target sequences, whereas R1333S (SpCas9 MT2 ) and R1335K (SpCas9 MT3 ) showed only background activity, which could be restored to wild-type levels in the presence of a ZFP fusion ( Fig. 2c and Supplementary Figs. 7 and 8).
To confirm that the ZFP-dependent restoration of activity was general, we assessed the nuclease activity of three additional SpCas9 MT3 -ZFP fusions, two of which restored nuclease function ( Supplementary Fig. 9 and Supplementary Table 1) . Thus, altering the affinity of PAM recognition through mutation generated SpCas9 variants that were dependent on the attached pDBD for efficient function. This pDBD dependence established a third stage of target-site licensing for our SpCas9 MT3 -pDBDs, which we believed would increase their precision.
Assessing the precision of spcas9 mt3 -ZFP fusions
Next we compared the precision of SpCas9 MT3 -ZFPs to that of SpCas9 using sgRNAs with previously defined off-target sites 14, 25 .
We programmed three different four-finger ZFPs to recognize 12-bp sequences neighboring sgRNA target sites 2, 3 and 4 (TS2, TS3 and TS4, respectively) for use as SpCas9 MT3 -ZFP fusions (Fig. 3a) . The activity of SpCas9, SpCas9 MT3 and SpCas9 MT3 -ZFP with the corresponding sgRNA was compared at each target site. In all cases SpCas9 MT3 dramatically decreased the cleavage efficiency, which was restored by the cognate ZFP fusion (Fig. 3b) .
The activity of SpCas9 MT3 -ZFP was dependent on the presence of both a cognate sgRNA and a cognate ZFP (Fig. 3c) . Consistent with the dependence on ZFP binding, truncation of one zinc finger from either end of ZFP TS3 decreased the activity of SpCas9 MT3 -ZFP TS3 at TS3, and the removal of two zinc fingers TS2   TS3 ZFP   TS3   TS3   TS3  TS3  TS3  TS3   TS3 TS3 TS3  TS3   TS3 Fig. 10 ). The additional stage of target-site licensing supplied by the pDBD dramatically increased the precision of SpCas9 MT3 -ZFP TS3 relative to that of wild-type SpCas9; lesion rates for sgRNA TS3 at off-target site 2 (OT3-2), the most active off-target site, were 22% by T7 endonuclease I (T7EI) assay with wild-type Cas9 but were undetectable with SpCas9 MT3 -ZFP TS3 (Fig. 3c) . We also programmed two TALE arrays to target SpCas9 MT3 to TS3 and TS4 (TALE TS3 and TALE TS4 ). Nuclease activity at TS3, but not at TS4, was restored by the related SpCas9 MT3 -TALE fusion (Supplementary Fig. 11) .
To examine the catalytic tolerance of the SpCas9 MT3 -ZFP TS3 : sgRNA complex for mismatches between the guide and a target sequence, we used a set of guides that progressively shifted blocks of two base mismatches from the 5′ to the 3′ end of the guide sequence. SpCas9 MT3 -ZFP TS3 had a lower tolerance for mismatches between the guide and target site than did wildtype SpCas9 (SpCas9 WT ), whereas SpCas9 WT -ZFP TS3 seemed to have a modestly increased tolerance for mismatches ( Fig. 3d and Supplementary Table 2 ). SpCas9 MT3 -ZFPs also exhibited decreased activity with truncated sgRNAs 25 ( Supplementary  Fig. 12 ), consistent with the requirement for a higher degree of guide-target site complementarity to achieve efficient cleavage.
deep-sequencing analysis of off-target activity
To more broadly assess improvements in precision, we deepsequenced PCR products spanning previously defined off-target sites for sgRNA TS2:TS3:TS4 (refs. 14,25) , as well as several additional genomic loci with favorable ZFP TS2:TS3:TS4 recognition sites and some complementarity to the TS2, TS3 or TS4 guide sequences (43 total; Supplementary Tables 3 and 4) . We compared the nuclease activity of SpCas9, SpCas9 MT3 , SpCas9 WT -ZFP TS2:TS3:TS4 and SpCas9 MT3 -ZFP TS2:TS3:TS4 at these off-target sites and found that SpCas9 MT3 -ZFP TS2:TS3:TS4 dramatically increased the precision of target-site cleavage (Fig. 4a) . In most cases, using SpCas9 MT3 -ZFP TS2:TS3:TS4 decreased lesion rates at off-target sites to background levels, resulting in up to 150-fold improvements in the specificity ratio (Fig. 4b) . Only one off-target site (OT2-2), which had a neighboring sequence similar to the expected ZFP TS2 recognition sequence (Supplementary Fig. 13 ), still had high lesion rates. One other site (OT2-6) showed some residual activity for both SpCas9 MT3 and SpCas9 MT3 -ZFP TS2 that was above the background error rate in our sequencing data. Overall, these data demonstrate a dramatic enhancement in precision for SpCas9 MT3 -ZFPs relative to that of standard SpCas9 at previously defined active off-target sites.
One potential advantage of the SpCas9-pDBD system over other Cas9 platforms is the ability to rapidly tune the affinity and specificity of the attached pDBD to further optimize its precision. Consequently, we sought to improve the precision of SpCas9 MT3 -ZFP TS2 by truncating the ZFP to reduce its affinity for target site OT2-2. Constructs with a truncation of either of the terminal zinc fingers showed high activity at the target site (Fig. 4c) . However, these truncations decreased or eliminated off-target activity at OT2-2, reflecting a profound improvement in the precision of SpCas9 MT3 -ZFP TS2 (Fig. 4c and Supplementary  Fig. 14) . Similarly, utilization of a ZFP (TS2*) that recognized 
Genomic target site variants that altered the number of zinc fingers or changed them completely (TS2*). The binding site for ZFP TS2* is indicated in green. Removing finger 1 (F2-4) or finger 4 (F1-3) from the four-finger TS2 ZFP array (F1-4) at most modestly affected the target-site activity, but it dramatically improved precision (dashed box). Data are from three independent biological replicates performed on different days in HEK293T cells (supplementary Fig. 14) . Error bars indicate ±s.e.m.
npg
an alternate sequence neighboring the TS2 guide target site also abolished off-target activity at OT2-2, confirming that cleavage by SpCas9 MT3 at this off-target site was ZFP dependent (Fig. 4c and Supplementary Fig. 4 ). Given the improvements in precision realized through these simple adjustments in the composition of the ZFP, it should be possible to achieve even greater enhancements in precision via more focused modification of the ZFP composition and the linker connecting it to SpCas9. Finally, we used genome-wide, unbiased identification of double-stranded breaks enabled by sequencing (GUIDE-seq) 17 to provide an unbiased assessment of the propensity for SpCas9 MT3 -ZFPs to cleave at alternate off-target sites in the genome. Using modified versions of the original protocol and bioinformatics pipeline, we assessed genome-wide double-stranded break induction by SpCas9 and SpCas9 MT3 -ZFP TS2:TS3:TS4 (Online Methods). This analysis revealed dramatically enhanced precision of the SpCas9 MT3 -ZFPs compared with that of SpCas9 for all three target sites ( Fig. 5 and Supplementary  Table 5 ). For SpCas9 MT3 -ZFP TS3 and SpCas9 MT3 -ZFP TS4 , we did not detect nuclease-dependent oligonucleotide capture at any site other than the target site. For SpCas9 MT3 -ZFP TS2 , which retained two active off-target sites that overlapped with SpCas9, cleavage activity at all of the alternate sequences was dramatically decreased compared with that of SpCas9. In addition, there was one new weak off-target site (OTG2-42) for SpCas9 MT3 -ZFP TS2 . These data demonstrate that use of the SpCas9 MT3 -ZFP fusion decreased cleavage at wild-type SpCas9 off-target sites without generating a new class of highly active ZFP-mediated off-target sites. discussion Our analysis of the activity of SpCas9-pDBD chimeras provides new insights into the mechanism of target-site licensing by SpCas9 and methods to exploit this mechanism to improve precision. Fusion of a pDBD to SpCas9 allows for efficient use of a broader repertoire of PAM sequences by SpCas9. However, even for SpCas9-pDBDs, there remains a dichotomy between functional and inactive PAMs. The broader targeting range of SpCas9-pDBDs probably reflects the bypass of a kinetic barrier to R-loop formation that follows PAM recognition, as proposed by Seidel and colleagues 6 . We believe that the pDBD tethering of SpCas9 leads to activity at a target site containing a suboptimal PAM by increasing the effective concentration of SpCas9 around the target site and hence stabilizing the SpCas9-PAM interaction 48 . For wild-type SpCas9, only high-affinity (NGG) PAM sites consistently have sufficient residence time to facilitate efficient npg progression to R-loop formation, but pDBD tethering increases the likelihood that SpCas9:sgRNA will be able to overcome this barrier at suboptimal PAMs. Our data also support an allosteric licensing mechanism, as described by Doudna and colleagues 5 , which is likely to restrict Cas9 nuclease activity for the majority of sequence combinations in the PAM element even with the increased local concentration afforded by pDBD tethering.
The enhanced sensitivity to guide-target site heteroduplex stability observed for our SpCas9 MT3 -ZFP TS3 chimera ( Fig. 3d and Supplementary Fig. 12 ) further supports the interplay between PAM recognition and guide complementarity in the licensing of nuclease activity. We found that mutations to the SpCas9 PAM-interacting domain introduced a third stage of licensing (pDBD site recognition) for efficient target-site cleavage in the SpCas9 MT -pDBD system (Fig. 5e) . The weakened interaction between mutant Cas9 and the PAM sequence necessitated an increased effective concentration for nuclease function that was achieved by the highaffinity interaction of the tethered pDBD with its target site. This combination dramatically improved precision as assessed by targeted deep-sequencing and GUIDE-seq analysis. Compared with previous GUIDE-seq analysis of TS2, TS3 and TS4 for SpCas9, we detected five, three and three of the top five off-target sites that were previously described 17 . The discrepancy between the studies could be due to our lower sequencing depth, the use of an alternate cell line or different delivery methods. Nonetheless, on the basis of our analysis we can exclude the presence of a new class of highly active off-target sites generated by the fusion of the ZFP to Cas9.
This system has important advantages over previously described Cas9 variant systems that improve precision 10, [25] [26] [27] [28] [29] [30] . The SpCas9 MT -pDBD system increased the targeting range of the nuclease by expanding the repertoire of highly active PAM sequences. This is in contrast to dimeric systems (e.g., dual nickases and FokI-dCas9 nucleases) that have a more restricted targeting range because of the requirement for a pair of compatible target sequences. Moreover, our system should be compatible with either of these dimeric nuclease variants, providing a further potential increase in precision while also expanding the number of compatible target sites for these platforms. In addition, the affinity and the specificity of the pDBD component can be easily tuned to achieve the desired level of nuclease activity and precision for demanding gene therapy applications. We programmed our SpCas9-ZFPs targeting TS2, TS3 or TS4 with four-finger ZFPs, as we believed that these would provide the optimal balance of specificity and affinity. In the case of SpCas9 MT3 -ZFP TS3 , this proved prudent (Supplementary Fig. 10 ). However, for SpCas9 MT3 -ZFP TS2 , we achieved improved precision with a three-finger ZFP, which demonstrates the flexibility provided by modular pDBDs. (More details on ZFP design for Cas9-ZFPs are provided in the Supplementary Discussion. Readers can refer to our website (http://mccb.umassmed.edu/Cas9-pDBD_search. html) for assistance with the identification of target sites and compatible ZFP sequences.) In addition to pDBD tuning, further optimization of the linker length and its composition can provide improvements in precision (and potentially activity) by further restricting the relative orientation and spacing of the SpCas9 and pDBD. Finally, it should be possible to generate Cas9-pDBD fusions for other Cas9 orthologs that have superior characteristics for gene therapy applications (for example, more compact Cas9 nucleases 49, 50 for viral delivery). Ultimately, for gene therapy applications where precision, activity and target-site location are of paramount importance, the expanded targeting range and precision achieved by the Cas9-pDBD framework provide a potent platform for the optimization of nuclease-based reagents that cleave a single target site in the human genome. nAture methods online methods Plasmid constructs. Our SpCas9-pDBD experiments used the following plasmids: All sgRNAs were expressed via a U6 promoter from pLKO1-puro 51 . All SpCas9 and SpCas9-DBD fusions were expressed via pCS2-Dest gateway plasmid under chicken β-globin promoter 52 . ZFPs were assembled as gBlocks (Integrated DNA Technologies) on the basis of previously described recognition preferences 53, 54 . ZFPs were cloned into a pCS2-Dest-SpCas9 plasmid backbone cloned through BspEI and XhoI sites. TALEs were assembled via golden gate assembly 55 into our JDS TALE plasmids 56 . Assembled TALEs were cloned into BbsI digested pCS2-Dest-SpCas9-TALEntry backbone through Acc65I and BamHI sites. Sequences of the SpCas9-pDBDs are listed in the Supplementary Note, and these plasmids will be deposited at Addgene for distribution to the community. Plasmid reporter assays of nuclease activity used the restoration of GFP activity through single-strand annealing (SSA)-mediated repair of an inactive GFP construct using the M427 plasmid developed by the Porteus laboratory 46 . SpCas9 target sites were cloned into plasmid M427 via ligation-independent methods after SbfI digestion. Mutations in the PAM-interacting domain of SpCas9 were generated by cassette mutagenesis.
Cell culture assay. HEK293T cells obtained from our collaborator M. Green (UMass Medical School, Worcester, Massachusetts, USA) were cultured in high-glucose DMEM with 10% FBS and 1% penicillin-streptomycin (Gibco) in a 37 °C incubator with 5% CO 2 . These cells were not verified or tested for mycoplasma contamination. For transient transfection, we used early to midpassage cells (passage numbers . Approximately 1.6 × 10 5 cells were transfected with 50 ng SpCas9-pDBD-expressing plasmid, 50 ng sgRNA-expressing plasmid and 100 ng mCherry plasmid with Polyfect transfection reagent (Qiagen) in a 24-well format according to the manufacturer's suggested protocol. For the SSA-reporter assay, 150 ng M427 SSA-reporter plasmid was also included in the cotransfection mix.
Western blotting. HEK293T cells were transfected with 500 ng Cas9 and 500 ng sgRNA-expressing plasmid in a six-well plate with Lipofectamine 3000 transfection reagent (Invitrogen) according to the manufacturer's suggested protocol. 48 h after transfection, cells were harvested and lysed with 100 µl of RIPA buffer. 8 µl of cell lysate was used for electrophoresis and blotting. The blots were probed with anti-hemagglutinin (Sigma, H9658) and anti-α-tubulin (Sigma, T6074) as primary antibodies, and then with horseradish peroxidase-conjugated anti-mouse IgG (Abcam, ab6808) and anti-rabbit IgG as secondary antibodies, respectively. For visualization we used Immobilon Western Chemiluminescent HRP substrate (EMD Millipore, WBKLS0100).
Flow cytometry reporter assay. 48 h after transfection, cells were trypsinized and collected in a microcentrifuge tube. Cells were centrifuged at 500g for 2 min, washed once with 1× PBS, recentrifuged at 500g for 2 min and resuspended in 1× PBS for flow cytometry (Becton Dickinson FACScan). For FACS analysis, 10,000 events were counted for each sample. To minimize the effect of differences in the efficiency of transfection among samples, cells were initially gated for mCherry expression, and the percentage of EGFP-expressing cells (nuclease-positive events) was quantified in mCherry-positive cells. All of the experimental replicates were performed in triplicate on different days; data are reported as mean ± s.e.m.
Genomic targeting analysis with T7EI
. 72 h after transfection, cells were harvested and genomic DNA was extracted using a DNeasy Blood and Tissue kit (Qiagen) according to the manufacturer's suggested protocol. 50 ng of input DNA was PCRamplified using T7EI primers that were specific for each genomic region (Supplementary Table 4 58 . Insertiondeletion percentages were calculated as previously described 57 . Experiments for T7EI analysis were performed in triplicate on different days; data are reported as mean ± s.e.m.
Targeted deep-sequencing-based off-target analysis for SpCas9-pDBDs. For the generation of each amplicon, we used two-step PCR amplification to first amplify the genomic segments and then install the barcodes and indexes. In the first step, we used 'locusspecific primers' bearing common overhangs with tails complementary to the TruSeq adaptor sequences (Supplementary Table 4) . 50 ng of input DNA was PCR amplified with Phusion High Fidelity DNA Polymerase (New England BioLabs): (98 °C, 15 s; 67 °C 25 s; 72 °C 18 s) for 30 cycles. 5 µl of each PCR reaction was gel-quantified by ImageJ 58 against a reference ladder, and equal amounts from each genomic-locus PCR were pooled for each treatment group (15 different treatment groups). The pooled PCR products from each group were run on a 2% agarose gel, and the DNA from the expected product size (between 100 and 200 bp) was extracted and purified with a QIAquick gel extraction kit (Qiagen). In the second step, we amplified the purified pool from each treatment group with a 'universal forward primer' and an 'indexed reverse primer' to reconstitute the TruSeq adaptors (Supplementary Table 4 58 , and then equal amounts of the products from each treatment group were mixed and run on a 2% agarose gel. Full-size products (~250 bp in length) were gel-extracted and purified with a QIAquick gel extraction kit (Qiagen). The purified library was deep-sequenced using a paired-end 150-bp MiSeq run.
Sequences from each genomic locus in a specific index were identified on the basis of a perfect match to the final 11 bp of the proximal genomic primer used for locus amplification (Supplementary Table 6 ). Insertions or deletions in the SpCas9 target region were defined on the basis of the distance between a 'prefix' sequence at the 5′ end of each off-target site (typically 10 bp) and a 'suffix' sequence at the 3′ end of each off-target site (typically 10 bp) 59 , where there were typically 33 bp between these elements in the unmodified locus (Supplementary Table 6 ). Distances that were greater than expected were binned as insertions, and distances that were shorter than expected were binned as deletions. Reads that did not contain the suffix sequence were marked as undefined. For some loci, the background sequencing error rate was high. For example, for OT2-1 a homopolymer sequence in the guide region led to a high error rate.
All statistical analyses were performed using R, a system for statistical computation and graphics 60 . Log-odds ratios of lesions were calculated for the on-target and off-target sites of each individual Cas9 treatment group versus the untreated control for each of the three independent experiments. A t-test was applied to assess whether the log-odds ratio was significantly different from 0, that is, whether there was a significant difference in lesion odds between each individual Cas9 treatment group and the untreated control for the on-target and off-target sites. We obtained odds ratios and their 99% confidence intervals by taking the exponents of the estimated log-odds ratios and their 99% confidence intervals. These analyses were also applied to the sum of the lesion rates across all three replicates (combined). To adjust for multiple comparisons, we adjusted P values using the Benjamini-Hochberg method 61 . Only loci that had significant Benjamini-Hochbergadjusted P values in the combined data for the treatment group relative to the control were considered significant. GUIDE-seq off-target analysis for SpCas9-pDBDs. We performed GUIDE-seq with some modifications to the original protocol 17 . Importantly, there is an error in the original publication with regard to the GSP1 and GSP2 primer sets, which list incompatible combinations. It was necessary to properly sort the primer sets for the positive (+) and negative (−) strands to achieve successful library amplification.
Nuclease_off_+_GSP1 GGATCTCGACGCTCTCCCTGTTTA ATTGAGTTGTCATATGTTAATAAC + Nuclease_off_-_GSP1 GGATCTCGACGCTCTCCCTATACC GTTATTAACATATGACA − Nuclease_off_+_GSP2 CCTCTCTATGGGCAGTCGGTGATT TGAGTTGTCATATGTTAATAACGGTA + Nuclease_off_-_GSP2 CCTCTCTATGGGCAGTCGGTGATA CATATGACAACTCAATTAAAC − In addition, our protocol differed from the published protocol 17 in the following manner: in a 24-well format, HEK293T cells were transfected with 250 ng of Cas9, 150 ng of sgRNA, 50 ng of GFP and 10 pmol of annealed GUIDE-seq oligonucleotide using Lipofectamine 3000 transfection reagent (Invitrogen) according to the manufacturer's suggested protocol. 48 h after transfection, genomic DNA was extracted with a DNeasy Blood and Tissue kit (Qiagen) according to the manufacturer's suggested protocol. Library preparations were done with original adaptors according to protocols described by Joung and colleagues 17 , with each library barcoded for pooled sequencing. The barcoded, purified libraries were deep-sequenced as a pool using two paired-end 150-bp MiSeq runs.
Reads containing identical molecular indices and identical starting 8-bp elements on read 1 were pooled into one unique read. The initial 30 bp and the final 50 bp of the unique read 2 sequences were clipped for removal of the adaptor sequence and low-quality sequences and then mapped to the human genome (hg19) using Bowtie2. Peaks containing mapped unique reads were identified using the pile-up program ESAT (http://garberlab. umassmed.edu/software/esat/) with a window of 25 bp with a 15-bp overlap. Neighboring windows that were on different strands of the genome and less than 50 bp apart were merged using Bioconductor package ChIPpeakAnno 62, 63 . Peaks that were present with multiple different guides (hot spots 17 ) or that did not contain unique reads for both sense and antisense libraries 17 were discarded. The remaining peaks were searched for sequence elements that were complementary to the nuclease target site using CRISPRseek 21 . Only peaks that harbored a sequence with fewer than seven mismatches to the target site were considered potential off-target sites. These regions are reported in Supplementary  Table 5 , and the numbers of reads from the sense and the antisense libraries were combined into the final read number.
CRISPRseek analysis of potential off-target site for SpCas9 sgRNAs. Human hg19 exon and promoter sequences were fetched using Bioconductor packages ChIPpeakAnno 62, 63 and TxDb. Hsapiens.UCSC.hg19.knownGene. A subset of 16,500 exons and 192 promoter sequences of 2 kb each were selected for sgRNA searching and genome-wide off-target analysis using Bioconductor package CRISPRseek 21, 22 with the default settings (both NGG and NAG PAMs were allowed), except BSgenomeName = BSgenome. Hsapiens.UCSC.hg19, annotateExon = FALSE, outputUniqueREs = FALSE, exportAllgRNAs = "fasta" and fetchSequence = FALSE. After sgRNAs with on-targets or/and off-targets in the haplotype blocks had been excluded, there were 124,793 unique sgRNAs from exon sequences and 55,687 unique guide RNAs from promoter sequences included in the analysis. Each guide was binned on the basis of either the off-target site with the fewest mismatches to the guide sequence or the sum of the off-target scores for the top ten off-target sites. The fraction of guides in each bin for exons or promoters is displayed as a pie chart (Supplementary Fig. 1 ).
Reproducibility. No statistical methods were used to predetermine sample size, and the investigators were not blinded to allocation during experiments and outcome assessment.
